Article
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Feb 2024
Duan Jianchun, Wu Lin, Yang Kunyu, Zhao Jun, Zhao Yanqiu, Dai Xiumei, Li Mingjun, Xie Yanyan, Yao Yu, Zhao Mingfang, Zhou Chengzhi, Ren Xiubao, Liu Zhe, Pan Yueyin, Li Yuping, Liu Baogang, Cheng Ying, Miao Liyun, Yu Qitao, Zhang Zhihong, Liu Xiaoqing, Cui Jiuwei, Zhang Yu, Zhang Li, Li Xiaoyan, Li Xiaoling, Shen Bo, Chen Bi, Zeng Shan, Li Bin, Hu Yanping, Li Lin, Wu Rong, Song Qibin, Wang Jie
Abstract excerpt
INTRODUCTION: Treatment options for treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations are limited. This study evaluated the safety, tolerability, and pharmacokinetics of YK-029A, a third-generation EGFR tyrosine kinase inhibitor, and the preliminary efficacy of YK-029A in treatment-naive patients with EGFR ex20ins mutation. METHODS: This multicenter,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.